1. Fend F, Dogan A, Cook JR (2023) Plasma cell neoplasms and related entities-evolution in diagnosis and classification. Virchows Arch, 482(1): 163-177. [DOI:10.1007/s00428-022-03431-3]

2. Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A (2012) A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. ScientificWorldJournal, 2012: 895765. [DOI:10.1100/2012/895765]

3. Dagan R, Morris CG, Kirwan J, Mendenhall WM (2009) Solitary plasmacytoma. Am J Clin Onco, 32(6): 612-7. [DOI:10.1097/COC.0b013e31819cca18]

4. Leng Y, Qiu L, Hou J, et al. (2016) Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma. Chin J Cancer, 35(1): 86. [DOI:10.1186/s40880-016-0140-0]

5. Albano D, Bosio G, Treglia G, et al. (2018) 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma. Eur J Nucl Med Mol Imaging, 45(1): 77-84. [DOI:10.1007/s00259-017-3810-5]

6. Lu YY, Chen JH, Lin WY, et al. (2012) FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: a systematic review and meta-analysis. Clin Nucl Med, 37(9): 833-837. [DOI:10.1097/RLU.0b013e31825b2071]

7. Durie BG, Waxman AD, D'Agnolo A, Williams CM (2002) Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med, 43(11): 1457-63.

8. Durie BG (2006) The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer, 42(11): 1539-43. [DOI:10.1016/j.ejca.2005.11.037]

9. Kato T, Tsukamoto E, Nishioka T, et al. (2000) Early detection of bone marrow involvement in extramedullary plasmacytoma by whole-body F-18 FDG positron emission tomography. Clin Nucl Med, 25(11): 870-3. [DOI:10.1097/00003072-200011000-00003]

10. Chirrmeister H, Buck AK, Bergmann L, et al. (2003) Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm, 18(5): 841-5. [DOI:10.1089/108497803770418382]

11. Korde N, Roschewski M, Zingone A, et al. (2015) Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol, 1(6): 746-754. [DOI:10.1001/jamaoncol.2015.2010]

12. Cavo M, Terpos E, Nanni C, et al. (2017) Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol, 18(4): e206-e217. [DOI:10.1016/S1470-2045(17)30189-4]

13. Fujima N, Hirata K, Shiga T, et al. (2018) Semi-quantitative analysis of pre-treatment morphological and intratumoral characteristics using 18F-fluorodeoxyglucose positron-emission tomography as predictors of treatment outcome in nasal and paranasal squamous cell carcinoma. Quant Imaging Med Surg, 8(8): 788-795. [DOI:10.21037/qims.2018.09.09]

14. Moon SH, Cho SK, Kim WS, et al. (2013) The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods. J Nucl Med, 54(7): 1039-44. [DOI:10.2967/jnumed.112.113399]

15. Sui H, Zhu Z, Li Z, Luo Y (2020) Primary Pancreatic Yolk Sac Tumor Presenting as Diffusely Enlarged Pancreas in Initial 18F-FDG PET/CT. Clin Nucl Med, 45(6): 483-486. [DOI:10.1097/RLU.0000000000003038]

16. Yao Y, Zuo Z, Cheng Z (2020). Isolated Nasal Metastasis From Renal Cell Carcinoma 9 Years After Nephrectomy Seen on FDG PET. Clin Nucl Med, 45(2): e110-e111. [DOI:10.1097/RLU.0000000000002836]

17. Fu Z, Liu M, Zhang J, et al. (2017) Nasal-tip metastasis on 18F-FDG PET/CT scan in a patient with squamous lung carcinoma. Clin Nucl Med, 42(6): 478-479. [DOI:10.1097/RLU.0000000000001597]

18. Wu J, Rao Z, Jiang G, et al. (2021) Detection of nasal solitary extramedullary plasmacytoma on 18F-FDG PET/CT imaging. Clin Nucl Med, 46(8): 677-678. [DOI:10.1097/RLU.0000000000003544]

19. Zhang L, Zhang X, He Q, et al. (2018) The role of initial 18F-FDG PET/CT in the management of patients with suspected extramedullary plasmocytoma. Cancer Imaging, 18(1): 19. [DOI:10.1186/s40644-018-0152-x]